• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    1-Nitro-9-hydroxyalkylaminoacridines or their salts of formula 1 <CHEM> wherein R is a normal or branched alkyl chain in which n = 2,3 or 4, useful as anti-neoplastic agents.
    公开号:SU1192620A3
    申请号:SU813270449
    申请日:1981-04-14
    公开日:1985-11-15
    发明作者:Высоцка-Скжэльа Барбара；Льэдуховски Анджэй；Радзиковски Чэслав
    申请人:Политехника Гданьска (Инопредприятие)；
    IPC主号:
    专利说明:

    3
    The precipitated orange precipitate was released from methanol with the addition of ether. The resulting hydrochloride 1 nitro-9 (1-hydroxybutyl) aminacridine with t, pl. with decomposition. Yield 90%.
    Chromatographic analysis.
    On neutral alumina (Merck) on the system benzene: acetone: methanol (3: 1: 1) Rf 0,65.
    On silica gel (Merck) in the butanol: acetic acid water (4: 1: 1) system, Rf is 0.50.
    Calculated,%: C 58.67; H 5.21; N 12.08.
    Found,%: C 58.69; H 5.20; N 12.16.
    The group of compounds according to the resistance possesses antitumor activity, which is similar, and in most tests even higher than the known compounds of this group. In addition, the proposed compounds do not exhibit emetic properties and also do not affect peripheral blood.
    The antitumor properties of this group of compounds, namely 1-nitro 9-hydroxyalkylaminoacridines, have been repeatedly studied using in vitro and in viv tests
    In vitro method.
    Inhibition of seed germination on the core is a growth test.
    On a Petri dish with a diameter of 80 mm, place the ZO- 25 seeds of a core on two layers of blotting paper, if possible evenly. Then on the cup. 30 ml of the test compound with a concentration of 1 mg / ml are poured, and distilled water is added to the control plates. The plates are incubated for 24 hours at 20-30 ° C, after which the length of the shoots is measured.
    The inhibition effect is expressed as a percentage of the decrease in the average length of the sprouts under study as compared with the control ones.
    The percent inhibition of seed germination of the core for the considered group of compounds is 87-94%.
    Method Miemura (Ehrlich cancer cells).
    The method consists in determining the inhibition of the activity of dehydrogenosis of Ehrlich cancer cells (5x10 per ml) by the test compounds measured by
    2620
    This is the diameter of the unrestored redox dye (resazurin) zone formed around a cylinder with an I% 5% solution of the test compound after a five hour incubation at 87 ° C.
    Compounds for which the braking zone is not less than 20 mm, O are considered active.
    The compounds in question show extremely high activity in this test, and it averages 31-33 mm. 5 Tissue culture (KB line),
    The studies were carried out according to the tissue culture method developed by Eagle and Foley, modified by Smith and his co-workers. 0 The experiment was carried out on tumor cells of human origin with the so-called liiii KB with the use of the nutrient medium Needle with the addition of 10% bovine serum. 5 Tests were carried out in test tubes grafted with 4 ml of suspension of f40-80 thousand cells), which is equivalent to 40-80 mg of cellular protein.
    The growth of the culture was determined by the increment of this cell protein; This determination was carried out photometrically using Folin-Sicaltan reagent by the method developed by Ohio and Dr.
    Simultaneously with grafting of the tubes into the cells, 0.9 ml of an aqueous solution of the test compound was added so that the concentration was: 100; ten; one; 0.1; 0.01; 0.001; and 0.0001 mg / ml nutrient medium. The tubes were incubated at 37 ° C. After 72 hours, the increase in cellular protein was determined in test tubes to which the preparation was added, as well as in control tubes.
    Each concentration was studied in parallel in two samples.
    Concentrations of the substance were determined, which are ensured by {{a 50% increase in cellular protein — LD 5d or EDj.
    Braking percentage calculated
    according to the formula:
    5 Residual amount of cellular protein zo control - terminal amount of cellular protein in the test
    % inhibition 100 The residual amount of cellular protein in the control is the initial amount of cellular protein in the control. In accordance with generally accepted standards, such compounds are considered active in which 1 centner / ml Compounds I have been tested by this method several times. For example, ED 5Q for one drug of this group, with the code symbol C-857, i.e. 1-nitro-9-hydroxyethylaminacrI dine, O, 0007 rg / ml, in vivo method. Inhibition of the growth of sarko-; we are Crocker (Sa-t80). For experiments, mice aged about 3 months were used. weighing about 25 g. They were vaccinated with a tumor cut (Over-180) and divided into groups: one control - 18 pieces and two to four groups of eight each treated. The studied compounds were administered into the peritoneum at the appropriate doses after a preliminary determination of the maximum tolerated dose (MID). As an evaluation of the antitumor effect of the test compounds, a percentage difference was taken between the average tumor weights of control mice and mice receiving the drug, taking into account the toxic effects of the test compound. The toxicity assessment covers the weight loss of treated animals compared to controls, the number of control animals killed, as well as microscopic histopathological studies. Such compounds, which at least twice inhibited tumor growth by more than 40%, are considered active, without causing a loss of animals (2 pieces) or average weight loss (4 g). In vivo studies in this test are considered groups of compounds. held multiple times. For example, for a drug with the code symbol C-857, i.e. 1-nitro-9-hydroxyethylamine acridine, the growth inhibition of Sa-lBO sarcoma was established depending on the following dose: at doses of 0.2-0.8 mg / kg, the percentage of inhibition was 44-86, respectively. Similarly, for a drug designated symbol C-934, i.e. 1-nitro-9-hydroxybutylamine acrida, at doses of 0.2-0.4 percent: inhibition was 45-60. Pharmacological studies. Toxicity studies of acute and cumulative, as well as basic pharmacological properties were carried out in the following tests: acute toxicity and determination of the maximum tolerated dose; cumulative toxic-. ness; effects on the circulatory system; effect on smooth muscle; effects on the central nervous system; immunosuppressive action. Acute toxicity (LD fp) and maximum tolerated dose (MTD) were determined on Wiater rats, rabbits (both sexes) and on Albino Swiss mice (females). . The compounds were injected into the peritoneum (in all three species of animals) and in the stomach (in rats and rabbits). The duration of the observation was 48 hours. In the table. 1 shows the following LD 50 and MTD values with the administration of compound C-857. Table 1 Mouse 23.4 15 Rat 9.2 7.5 69.1 30 Rabbit 11.4 7.5 69.0 20. Cumulative toxicity. The experiment was carried out on several groups of rats (iio 20 pcs.), By which the test compound was administered for 14–14 days at doses of 1/100. The animals were then sacrificed, after which a microscopic evaluation of the muscular organs and the abdominal cavity was carried out. It should be assumed that the studied drug cumulates to a minimum degree — the mortality of animals receiving the drug, compared with the control, was about 5%. Neither was weight loss of animals, nor changes in their appearance and behavior observed. 7 A study on the effect on the circulatory system and smooth blood was conducted on rats that were injected with compound C-857 up to from 0.01 to 20 mg / kg. The drug did not cause noticeable changes in the studied cardiovascular parameters, i.e. did not affect blood pressure, heart rate, did not simulate the ECG curve, and did not affect the frequency and amplitude of respiration. Only at the highest dose (20 mg / kg) did the drug reveal a weak spasmolytic effect on the rat intestine and bladder in situ. The drug did not reveal a noticeable and directed effect on the central nervous system. At doses of 1 / 20-1 / 2 LDjQ, he did not detect an analgesic and anticonvulsant effect and a substantial inhibition of mobility, but there was little effect on hexobarbital anesthesia. 08 The drug only after repeated administration in doses of about 1 / 5-1 / It) LDj-Q revealed the immunosuppressive effect exhibited in the tests: contact sensitization with picryl chloride, a local cellular reaction such as graft versus recipient, as well as joint inflammation of joints . A study of the subacute toxicity of the drug C-857 was carried out on rabbits, which were injected into the peritoneum with a drug in a dose of 1/120 U) Q. After 21 days, a slight decrease in the absolute weight of the spleen and liver was found, as well as an increase in the number of leukocytes. The remaining hematologic definitions did not differ from those performed in normal animals. In tab. Figure 2 presents a comparative analysis of biological studies of Ledacrine with compounds 1 after intragastric administration of the drug. table 2
    权利要求:
    Claims (2)
    [1]
    1, A method for producing 1-nitro-9- —oxyalkylaminoacridines of the general formula
    NO2 NH- CH (CH 2 ) p 0H
    Where at R - Η, η = 1, 2 or h; at R - With 2 N , η = one, or their hydrochlorides, about t l and h y u and th with i the fact that solution 1—
    -nitro-9-phenoxyacridine in phenol is treated with hydroxyalkylamine or its hydrochloride when their ratio is 1: 1,
    О * after which it is heated to 60–100 С, the resulting mixture is cooled and poured into an excess of nonpolar organic solvent, the precipitated precipitate is filtered off and crystallized from a non-aqueous polar organic solvent or their mixture, followed by isolation of the target product in its free form or as hydrochloride
    [2]
    2. The method according to π. 1, why is it that ethyl ether or benzene is used as non-polar organic solvents and polar solvents are methanol, ethanol or a mixture thereof.
    类似技术:
    公开号 | 公开日 | 专利标题
    Cobb et al.1969|2, 4-dinitro-5-ethyleneiminobenzamide |: a potent and selective inhibitor of the growth of the Walker carcinoma 256
    US5482954A|1996-01-09|Signal transduction inhibitor triazole and diazole compounds
    Ishiyama et al.1996|A combined assay of cell vability and in vitro cytotoxicity with a highly water-soluble tetrazolium salt, neutral red and crystal violet
    Showalter et al.1984|5-[| amino]-substituted anthra [1, 9-cd] pyrazol-6 |-ones as novel anticancer agents. Synthesis and biological evaluation
    SU1192620A3|1985-11-15|Method of producing 1-nitro-9-oxyalkylaminoacridines or chlorine hydrates thereof
    US4150231A|1979-04-17|1-Nitro-9-dialkylaminoisoalkylaminoacridines or their salts
    US4146720A|1979-03-27|N-aminoethyl-substituted-3-nitronaphthalimides
    US4139531A|1979-02-13|1-Nitro-9-alkylaminoalkylaminoacridines and salts thereof
    US4272538A|1981-06-09|5-Nitro-imidazole with antiprotozoic activity
    FI69450B|1985-10-31|FOERFARANDE FOER FRAMSTAELLNING AV NYA SOM IMMUNSTIMULANTER ANAENDBARA DI-0-N-ALKYLGLYCEROLDERIVAT
    US5776859A|1998-07-07|Sodium channel active novel compounds and related processes and bioassay techniques
    SU1616520A3|1990-12-23|Method of producing derivatives of pristinamicine
    US4317835A|1982-03-02|Novel basic substituted-alkylidenamino-oxyalkyl-carboxylic acid esters
    Urbański et al.1956|Biological activity of benzoxazine-1, 3 derivatives, particularly against experimental sarcoma
    US4598081A|1986-07-01|1,3-dioxo-1H-benz|isoquinoline-2| butyric acid, pharmacologically acceptable salts thereof and compositions containing the same for treatment of diabetes mellitus complications
    Baguley et al.1982|DNA binding and growth inhibitory properties of a series of 2, 7-di-alkyl-substituted derivatives of proflavine
    Read et al.1973|Compound 48/80. Structure-activity relations and poly-THIQ [tetrahydroisoquinoline], a new, more potent analog
    US4170640A|1979-10-09|Antibiotic mixtures
    US5498620A|1996-03-12|Signal transduction inhibitor 1,2,3-triazolo compounds
    Shimizu et al.1983|Mutagenic activity of N-nitrosomethamphetamine and N-nitrosoephedrine
    US5374739A|1994-12-20|Mitomycin analogs
    US5880129A|1999-03-09|Methods of inhibiting invasion and metastasis of malignant solid tumors
    SE437931B|1985-03-25|PHARMACEUTICAL COMPOSITION WITH ANTITUMOR EFFECTS CONTAINING PHOSPHATE OF POLYHEXAMETHYLENGUANIDINE WITH THE FORMULA
    Savornin et al.1991|Evaluation of in‐vitro leishmanicidal activity of hydrazones of thiophene carboxaldehydes against promastigotes of Leishmania infantum and Leishmania tropica
    JP2988937B2|1999-12-13|Novel antitumor and antiviral compositions from marine sources
    同族专利:
    公开号 | 公开日
    HU182322B|1983-12-28|
    PL223740A1|1981-11-13|
    PL126407B1|1983-07-30|
    SU1168557A1|1985-07-23|
    JPS56166176A|1981-12-21|
    EP0038572B1|1984-03-21|
    DE3162752D1|1984-04-26|
    EP0038572A1|1981-10-28|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    NL10194C|
    PL60640B1|1967-08-28|1970-08-20|Przedsiębiorstwo Państwowe|Method for the preparation of N9-substituted 1-nitro-9-aminoacridines|
    PL106752B1|1976-02-25|1980-01-31|Politechnika Gdanska|HOW TO RECEIVE NEW 1-NITRO-9-ALKYL-ALKYL-ALKYL-ACID AND OR THEIR SALT|
    PL101032B1|1976-04-06|1978-11-30|METHOD OF OBTAINING 1-NITRO-9-DUALKYL-AMINOIZOALKYLAMIROACRIDINES OR THEIR SALTS|DE19904437A1|1999-02-04|2000-08-10|Ceramtec Ag|Clamp-fit connection between prosthetic components of joint prostheses|
    US6589961B2|2000-02-18|2003-07-08|New York Medical College|9-alkylamino-1-nitroacridine derivatives|
    EP1257538B1|2000-02-18|2010-09-08|New York Medical College|9-alkylamino-1-nitroacridine derivatives|
    PT1261325E|2000-02-18|2010-12-10|New York Medical College|Tumor inhibiting compositions comprising nitroacridines|
    EP3070078B1|2015-03-20|2017-10-04|Politechnika Gdanska|Asymmetric bis-acridines with antitumor activity and use thereof|
    PL425847A1|2018-06-07|2019-12-16|Gdański Uniwersytet Medyczny|New dye for fluorescent dyeing of horny layer of epidermis , method for obtaining it and its application in microscopy, including for identification of ways of penetration into skin and evaluation of structural disorders of that layer|
    法律状态:
    优先权:
    申请号 | 申请日 | 专利标题
    PL1980223740A|PL126407B1|1980-04-23|1980-04-23|Process for preparing 1-nitro-9-hydroxyalkylaminoacridines or their salts|
    [返回顶部]